Cannabis for Chronic Diarrhea
Small evidence of symptom relief in IBD, but not a disease-modifying treatment; serious risks with heavy use.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
Cannabis slows the gut through CB1 receptor activation—that's pharmacology, not folklore. In Crohn's disease and ulcerative colitis, small trials show it reduces symptoms and improves quality of life, but it doesn't heal inflammation. For other causes of chronic diarrhea, there's almost no human data. Heavy use risks cannabinoid hyperemesis syndrome, which makes diarrhea worse. It's not a first-line or disease-modifying treatment.
Plain-Language Summary
Chronic diarrhea—loose or frequent stools lasting more than four weeks—can result from inflammatory bowel disease (IBD), irritable bowel syndrome with diarrhea (IBS-D), microscopic colitis, bile acid malabsorption, celiac disease, infections, medications, and other causes. The right treatment depends on identifying the underlying problem.
Cannabis interacts with the gut through the endocannabinoid system. The CB1 and CB2 receptors are expressed throughout the gastrointestinal tract, and when activated, they tend to slow intestinal motility and reduce fluid secretion Strong evidence [1][2]. This is why cannabis can make stools firmer and less frequent. However, slowing the gut is only a symptomatic effect—it does not address or heal the underlying disease.
The strongest human clinical data comes from small randomized trials in inflammatory bowel disease, where cannabis improves patient-reported symptoms and quality of life but does not appear to reduce inflammation or promote healing of the intestinal lining Weak / limited [3][4][5]. For most other causes of chronic diarrhea, high-quality clinical trials do not exist.
⚠️ This article is educational and is not medical advice. Chronic diarrhea can signal serious disease including colorectal cancer, celiac disease, or active infection. Consult a gastroenterologist or your primary care clinician before self-treating, especially if you have not had a diagnostic workup.
What Probably Works (Relatively Speaking)
Symptomatic relief in IBD. Small randomized controlled trials in Crohn's disease and ulcerative colitis have shown that inhaled or oral THC-rich cannabis improves patient-reported diarrhea, abdominal pain, appetite, and overall quality of life Weak / limited [3][5]. A 2013 Israeli trial by Naftali et al. found clinical improvement in Crohn's symptoms with smoked cannabis, though inflammatory markers such as C-reactive protein did not consistently improve [3]. Subsequent studies have reinforced the pattern: symptom benefit without objective healing of inflammation Weak / limited [4][5]. These trials involved 20–50 participants typically; larger confirmatory trials have not been conducted.
Pharmacological mechanism is established. CB1 agonism demonstrably slows small-bowel and colonic transit in both animal and human physiological studies Strong evidence [1][2]. Therefore, the basis for 'THC firms stools' is real pharmacology, not folklore. What remains uncertain is whether this symptomatic effect translates to meaningful long-term benefit in most patients, and whether symptom improvement persists over months or years.
What Might Work
IBS-D (irritable bowel syndrome with diarrhea). The endocannabinoid system is plausibly involved in IBS pathophysiology, and a small trial of dronabinol (synthetic THC) in IBS-D patients showed reduced colonic motility and modest symptom improvement in some participants Weak / limited [6]. However, results are mixed, effect sizes are small, and larger confirmatory trials have not been published.
Cannabis as an alternative to loperamide or opioid antidiarrheals. In patients already using peripheral antimotility drugs (loperamide, diphenoxylate) and tolerating them poorly, low-dose THC is pharmacologically reasonable because CB1 activation engages overlapping downstream signaling with mu-opioid activation on gut transit Weak / limited [2]. This theoretical basis has not been tested in a head-to-head clinical trial comparing cannabis to standard antidiarrheals in chronic diarrhea.
CBD (cannabidiol) alone. Preclinical data in animal models suggest CBD reduces intestinal inflammation and hypermotility Weak / limited [7]. A small human randomized trial of CBD-rich extract in ulcerative colitis did not meet its primary endpoint for symptom improvement Weak / limited [8]. On current human evidence, CBD is not a reliable antidiarrheal agent.
What Doesn't Work or Lacks Evidence
'Indica for diarrhea, sativa for constipation.' This is folklore. The indica/sativa distinction does not reliably predict pharmacological effects on the gut or any other system No data. Chemotype (THC/CBD ratio and minor cannabinoid profile) is more relevant than plant morphology, and even then, person-to-person variation is large.
Cannabis for infectious diarrhea. No evidence supports cannabis for bacterial (e.g. Clostridioides difficile, traveler's diarrhea) or viral gastroenteritis No data. Slowing gut transit during toxin-mediated infections can be harmful and prolong illness.
Cannabis for chemotherapy-induced diarrhea. Cannabinoids are used for chemo-induced nausea and vomiting, but there is no meaningful human evidence for chemotherapy-induced diarrhea specifically No data.
Cannabis as a disease-modifying or anti-inflammatory treatment in IBD. Repeated clinical trials show that cannabis improves subjective symptoms without objective improvement in inflammation, endoscopy scores, or biomarkers such as fecal calprotectin or C-reactive protein Strong evidence [3][4][5]. It does not induce or maintain remission of the underlying disease.
High-dose or heavy chronic use for symptom control. Chronic cannabis use to manage diarrhea escalates risk, and paradoxically, heavy chronic use can precipitate cannabinoid hyperemesis syndrome (CHS), a cyclic disorder of nausea, vomiting, and abdominal pain that closely mimics or worsens the very symptoms patients are attempting to treat Strong evidence [9].
What We Don't Know
- Optimal THC:CBD ratio or dose for GI symptom control.
- Whether oral, sublingual, or inhaled routes yield different diarrhea-specific outcomes.
- Long-term effects on the gut microbiome and mucosal immune function.
- Whether cannabis helps bile acid malabsorption diarrhea, microscopic colitis, post-cholecystectomy diarrhea, or other specific causes—essentially no trial data exist for these conditions.
- Whether genetic variants, disease subtype, endocannabinoid system tone, or other factors predict which patients will respond.
- Optimal duration of use before risks (dependence, hyperemesis syndrome) outweigh symptom benefits.
Comparison with Standard Treatments
Standard first-line treatments for chronic diarrhea are tailored to the underlying cause:
- Loperamide (Imodium): peripheral mu-opioid agonist, does not cross the blood-brain barrier at normal doses, decades of safety data, inexpensive, available over-the-counter in most countries [10].
- Diphenoxylate/atropine (Lomotil): prescription, similar mechanism.
- Bile acid sequestrants (cholestyramine, colesevelam): for bile acid–mediated diarrhea.
- Rifaximin: for IBS-D and small intestinal bacterial overgrowth.
- Eluxadoline, alosetron: FDA-approved specifically for moderate-to-severe IBS-D.
- Disease-specific therapy: 5-ASA compounds, corticosteroids, and biologic agents (TNF inhibitors, interleukin inhibitors) for IBD; gluten-free diet for celiac disease; etc.
Cannabis has not been shown superior to any of these for any specific diarrhea indication in controlled trials No data. Any potential role would be as an add-on for patients with IBD or IBS-D whose symptoms and quality of life remain poor despite standard therapy—a use case supported only by small, short-term trials, not by large randomized controlled trials or long-term follow-up data.
Risks and Practical Cautions
Cannabinoid hyperemesis syndrome (CHS). Long-term heavy cannabis use can produce cyclic episodes of nausea, vomiting, and abdominal pain—paradoxically worsening or mimicking the very GI symptoms patients are trying to treat Strong evidence [9]. CHS typically improves after cessation of cannabis but can recur with resumed use.
Cognitive and motor impairment. THC causes short-term impairment of attention, memory, reaction time, and motor coordination. It is not suitable if you operate machinery, drive, or care for dependents while dosed.
Dependence and withdrawal. Regular cannabis use can produce cannabis use disorder in approximately 9% of adult users (higher in adolescents and daily users) Strong evidence [11]. Withdrawal symptoms include irritability, anxiety, sleep disturbance, and decreased appetite.
Drug interactions. CBD inhibits hepatic CYP3A4 and CYP2C19 enzymes and can increase levels of warfarin, some antiepileptic drugs, and certain immunosuppressants used in IBD (such as calcineurin inhibitors) Weak / limited [12]. Cannabis and Polypharmacy Risks discusses these interactions in detail.
Masking serious disease. Chronic diarrhea can be the presenting symptom of inflammatory bowel disease, celiac disease, colorectal malignancy, or chronic infectious diseases. Self-treating with cannabis without diagnostic investigation risks delayed or missed diagnosis of treatable conditions.
Pregnancy and breastfeeding. Avoid cannabis entirely during pregnancy and lactation; cannabinoids cross the placenta and are secreted in breastmilk, and prenatal and early postnatal exposure has been associated with neurodevelopmental effects in observational studies.
⚠️ This article is educational and is not medical advice. Speak with a gastroenterologist or your prescribing clinician before using cannabis to manage chronic diarrhea, particularly if you have IBD, are taking immunosuppressants or anticoagulants, or have not completed a diagnostic workup for your diarrhea.
Sources
- Peer-reviewed Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacology & Therapeutics. 2010;126(1):21–38.
- Peer-reviewed Camilleri M. Cannabinoids and gastrointestinal motility: pharmacology, clinical effects, and potential therapeutics in humans. Neurogastroenterology & Motility. 2018;30(9):e13370.
- Peer-reviewed Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology. 2013;11(10):1276–1280.
- Peer-reviewed Kienzl M, Storr M, Schicho R. Cannabinoids and opioids in the treatment of inflammatory bowel diseases. Clinical and Translational Gastroenterology. 2020;11(1):e00120.
- Peer-reviewed Naftali T, Bar-Lev Schleider L, Sklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: a randomized controlled trial. PLOS ONE. 2021;16(2):e0246871.
- Peer-reviewed Wong BS, Camilleri M, Busciglio I, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011;141(5):1638–1647.
- Peer-reviewed Couch DG, Tasker C, Theophilidou E, Lund JN, O'Sullivan SE. Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clinical Science. 2017;131(21):2611–2626.
- Peer-reviewed Irving PM, Iqbal T, Nwokolo C, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflammatory Bowel Diseases. 2018;24(4):714–724.
- Peer-reviewed Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. Journal of Medical Toxicology. 2017;13(1):71–87.
- Peer-reviewed Schiller LR, Pardi DS, Sellin JH. Chronic diarrhea: diagnosis and management. Clinical Gastroenterology and Hepatology. 2017;15(2):182–193.
- Peer-reviewed Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015;72(12):1235–1242.
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug–drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Crohn's Disease — Cannabis relieves Crohn's symptoms but does not heal bowel inflammation—understand the evi...
- Cannabis and Opioid Substitution — Cannabis shows weak evidence for opioid-sparing in chronic pain; no established role in ad...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.